share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K:诺和诺德-股票回购计划
美股SEC公告 ·  08/26 10:46

Moomoo AI 已提取核心信息

Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on August 26, 2024. The program, which began on February 6, 2024, aims to repurchase up to DKK 20 billion worth of shares over a 12-month period. As part of this initiative, a specific share repurchase plan was initiated on August 7, 2024, targeting the repurchase of B shares for an amount up to DKK 2.4 billion, to be completed by November 4, 2024. Since the last update on August 19, 2024, Novo Nordisk has acquired an additional 205,000 B shares at an average price of approximately DKK 914.16, amounting to a transaction value of DKK 187,386,081. This brings the total repurchased under the program to 540,187 B shares, with an accumulated transaction value of DKK 485,999,068. The company...Show More
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on August 26, 2024. The program, which began on February 6, 2024, aims to repurchase up to DKK 20 billion worth of shares over a 12-month period. As part of this initiative, a specific share repurchase plan was initiated on August 7, 2024, targeting the repurchase of B shares for an amount up to DKK 2.4 billion, to be completed by November 4, 2024. Since the last update on August 19, 2024, Novo Nordisk has acquired an additional 205,000 B shares at an average price of approximately DKK 914.16, amounting to a transaction value of DKK 187,386,081. This brings the total repurchased under the program to 540,187 B shares, with an accumulated transaction value of DKK 485,999,068. The company now holds 12,935,944 B shares as treasury shares, which is 0.3% of the share capital. The total number of A and B shares, including treasury shares, is 4,465,000,000. Since the start of the repurchase program, Novo Nordisk has bought back 11,607,313 B shares at an average price of DKK 879.94 per share, totaling DKK 10,213,705,118. Novo Nordisk is committed to defeating serious chronic diseases and employs approximately 69,000 people across 80 countries.
诺和诺德(Novo Nordisk A/S)是一家领先的全球医药健康公司,在2024年8月26日宣布了其回购计划的进展。该计划始于2024年2月6日,旨在在12个月内回购价值200亿丹麦克朗的股份。作为该计划的一部分,于2024年8月7日启动了特定的股份回购计划,目标是回购B股,金额高达24亿丹麦克朗,将于2024年11月4日前完成。自2024年8月19日最后更新以来,诺和诺德以平均价格约为914.16丹麦克朗的价格收购了额外的2050000亿股,交易金额为187,386,081丹麦克朗。这使得该计划下回购的股票总数达到5401870亿股,累计交易金额为485,999,068丹麦克朗。公司现持...展开全部
诺和诺德(Novo Nordisk A/S)是一家领先的全球医药健康公司,在2024年8月26日宣布了其回购计划的进展。该计划始于2024年2月6日,旨在在12个月内回购价值200亿丹麦克朗的股份。作为该计划的一部分,于2024年8月7日启动了特定的股份回购计划,目标是回购B股,金额高达24亿丹麦克朗,将于2024年11月4日前完成。自2024年8月19日最后更新以来,诺和诺德以平均价格约为914.16丹麦克朗的价格收购了额外的2050000亿股,交易金额为187,386,081丹麦克朗。这使得该计划下回购的股票总数达到5401870亿股,累计交易金额为485,999,068丹麦克朗。公司现持有129359440亿股作为库藏股,占股本的0.3%。A股和B股的总股本,包括库藏股,为4,465,000,000股。自回购计划开始以来,诺和诺德以平均价格879.94丹麦克朗每股回购了116073130亿股,总额为10,213,705,118丹麦克朗。诺和诺德致力于战胜严重的慢性疾病,公司在80个国家拥有约69,000名员工。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息